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Research
At the request of the U.S. Environmental
Protection Agency (EPA) Ofﬁce of Research
and Development (ORD), the Board of
Scientific Counselors (BOSC) Executive
Committee (U.S. EPA 2005a) organized and
conducted an independent and open peer
review of the Endocrine Disrupting Chemicals
Research Program (EDC Research Program)
of the U.S. EPA. In May 2004 the BOSC
formed a subcommittee to conduct the review,
including individuals from academia, industry,
private consulting, and other agencies. The
subcommittee members (co-authors of this
article) have expertise specific to endocrine-
disrupting chemicals (EDCs) and related areas,
with research that has considerable overlap
with the U.S. EPA-sponsored EDC Research
Program. Three members (A. Harding,
G. Daston, and J. Stewart) were also members
of the BOSC Executive Committee.
The subcommittee was charged with
reviewing the design, relevance, progress, sci-
entific leadership, and resources of the pro-
gram (Appendix 1) and providing a report to
the BOSC Executive Committee. Our purpose
was to review the progress of the U.S. EPA in
establishing and managing an effective cross-
disciplinary and cross-functional program in
endocrine disruptors that addresses the needs
that the U.S. EPA has already articulated in its
Research Plan for Endocrine Disruptors
(Research Plan; U.S. EPA 1998a) and its
Multiyear Plan (MYP) for Endocrine Disrup-
tors (U.S. EPA 2003a). It was not our purpose
to create a new research agenda or to critique
the existing one. In this report we summarize
the ﬁndings from the review of the program
by the subcommittee.
Background 
In the early 1990s scientists began to synthe-
size information about the potential impacts
of endocrine-mediated toxicity on humans
and wildlife, arriving at the hypothesis that
weakly endocrine-active compounds in the
environment were having signiﬁcant adverse
effects on public and environmental health
(Colborn and Clement 1992). In response to
these earlier ﬁndings, the U.S. EPA convened
two international workshops in 1995 (Ankley
et al. 1997; Kavlock et al. 1996) to identify
uncertainties and research needs relative to
future risk assessments for EDCs. These
workshops reported effects on reproductive,
neurologic, and immunologic function, and
carcinogenesis as the major end points of con-
cern and recommendations for research and
also served as the basis for establishing
national and international research efforts.
The MYP (U.S. EPA 2003a) on endocrine
disruptors covers a considerable fraction of the
research identified by the scientific commu-
nity as being important for understanding the
impact of EDCs. 
A recent publication identifies 10 key
areas of uncertainty that must be addressed to
determine the significance of endocrine dis-
ruptors as public and ecologic health threats
(Daston et al. 2003).The relationship of these
key research questions to the long-term goals
in the MYP are shown in Appendix 2. In
1996, ORD identiﬁed EDCs as one of its top
six research priorities. In the same year,
through the enactment of the Food Quality
Protection Act of 1996 (FQPA 1996), the
U.S. Congress directed the U.S. EPA to
screen pesticides for estrogenic activity in
humans using validated studies or other scien-
tifically relevant information and gave the
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agency discretionary authority to screen for
other endocrine effects as well. The Safe
Drinking Water Act Amendments of 1996
(SDWA 1996), passed in the same year,
authorized the U.S. EPA to screen drinking
water contaminants for similar activities. To
implement the legislation, a number of scien-
tific questions needed to be addressed and
resolved through research. Consequently, the
U.S. EPA EDC Research Program and the
development and implementation of a man-
dated Endocrine Disruptor Screening
Program (EDSP) by the Ofﬁce of Prevention,
Pesticides, and Toxic Substances (OPPTS) are
on parallel yet highly interactive tracks (U.S.
EPA 2005b).
The peer-reviewed blueprint for the U.S.
EPA EDC Research Program was published in
1998 as the ORD Research Plan and took into
consideration the advice provided to OPPTS
on the implementation of the legislation by an
independent expert advisory panel (U.S. EPA
1998a). Five years later, ORD developed the
MYP (U.S. EPA 2003a) that identiﬁes the ele-
ments of the Research Plan that speciﬁcally will
be addressed over the next 5–10 years, intra-
murally, across three national laboratories and
one national center and, extramurally, through
a competitive grants program. 
The purpose of the MYP is to provide a
framework that integrates research across the
laboratories and centers of the ORD to pro-
duce scientiﬁcally credible results in accordance
with the Government Performance and Results
Act (Ofﬁce of Management and Budget 2005)
goals and supports the agency’s mission to pro-
tect human health and the environment. The
MYP identiﬁes long-term goals (LTGs), and
presents annual performance goals and associ-
ated annual performance measures for a plan-
ning window of approximately 5–10 years
(Appendix 2). The MYP fosters the integration
of strategic risk-based environmental protec-
tion and anticipation of future environmental
issues by communicating the research
approach and timing for responding to envi-
ronmental issues. The MYP will be updated
every 2 years to reﬂect the current state of the
science, resource availability, and agency priori-
ties, and reflects research activities imple-
mented and planned for 2000 through 2012. 
In addition to the MYP, which identiﬁes
the EDC research directions for all the labora-
tories and centers of the ORD, some ORD
organizations have developed their own imple-
mentation plans. For example, the National
Risk Management Research Laboratory
(NRMRL) of the ORD has developed a Risk
Management Evaluation (Sayles et al. 2002),
and the National Health and Environmental
Effects Research Laboratory (NHEERL) has
developed a Research Implementation Plan
(U.S. EPA 2004a) to guide the speciﬁc activi-
ties of that laboratory that are related to EDCs. 
Program Review Materials
The subcommittee reviewed materials sent by
the U.S. EPA, including the Research Plan
(U.S. EPA 1998a), the MYP (U.S. EPA 2003a),
the NHEERL Research Implementation
Plan (U.S. EPA 2004a), a bibliography of
publications by intramural and extramural
researchers, proceedings and abstracts from
recent EDC workshops (U.S. EPA 2002a,
2003b), abstracts of the posters to be pre-
sented at the program review meeting, and
biographical sketches of the intramural and
extramural researchers. Additional reports
(American Chemistry Council 1999; Damstra
et al. 2002; U.S. EPA 1998b, 2002b, 2004b)
were also made available to the subcommittee
prior to the 13–14 December 2004 face-to-
face meeting. 
The U.S. EPA staff provided an overview
of the EDC Research Program and the LTGs,
and poster sessions were presented and
discussed by intramural and extramural
researchers, program and regional ofﬁce scien-
tists, and grantees. Poster sessions were fol-
lowed by presentations by representatives from
program and regional ofﬁces who spoke to the
relevance of the research program. The meet-
ing included an opportunity for public com-
ment. At the conclusion of the meeting, the
subcommittee presented a draft oral report of
its ﬁndings.
The subcommittee organized the review
based on the three LTGs presented in the
MYP (U.S. EPA 2003a), commenting and
responding to the ﬁrst three charge questions
(program design, program relevance, program
progress/performance) for each long-term
goal. Charge questions four and ﬁve (leader-
ship and resource allocation) were evaluated
separately, as they cross-cut the overall pro-
gram (Appendix 1). The full report of the sub-
committee can be accessed at the BOSC
website (BOSC 2005). Highlights of the ﬁnd-
ings of the subcommittee are presented below.
Peer-Review Subcommittee
Findings
Long-term goal 1. LTG 1 strives to provide the
science underlying the effects, exposure, risk
assessment, and risk management of EDCs.
The goals set forth in the Research Plan and the
MYP to address the underlying science needs
for risk assessment and management of EDCs
continue to be appropriate. The research and
implementation plans to achieve these goals are
well founded and provide a logical framework
for attaining the Research Plan goals. 
LTG 1 is well designed and takes advantage
of existing core competencies in reproductive
toxicology, mechanistic toxicology, ecotoxicol-
ogy, risk assessment, and risk management
methodology to address these questions. The
capabilities of these scientists are unique in
breadth, depth, and scope within the federal
government. No other federal agency is
equipped to provide answers regarding both
risk assessment and management of EDCs.
Thus, the outcomes of the Research Plan
continue to provide essential, fundamental sci-
entiﬁc support for other regulatory and resource
management agencies, both federal and state, as
well as external investigators and industry.
The EDC Program has relied on the
Science to Achieve Results (STAR) grants pro-
gram to conduct research and provide expertise
to achieve program-related outcomes related to
LTG 1. STAR grant recipients have con-
tributed important findings on many topics
including interspecies differences in steroid
receptors, avian and invertebrate models for
EDC evaluations, and the effects of multiple
EDC exposures. The Research Plan has also
utilized and relied on the skills and abilities of
scientists from other federal agencies to com-
plement some activities in this research area.
The STAR program, therefore, is an essential
element in the EDC Program to continue to
meet its goals outlined in the Research Plan.
One example of the plan’s reliance on extra-
mural expertise is in avian toxicology. The
expertise to conduct avian toxicology studies in
the laboratory or in the field does not reside
within the U.S. EPA/ORD.
The science conducted under LTG 1 is
unique and provides the foundation required
for future risk assessment and risk management
activities legislatively mandated to the U.S.
EPA. Work on development of models (mam-
malian, ﬁsh, amphibian, and avian) is ongoing,
with appropriate end points to help identify
and evaluate uncertainties for human and eco-
logic risk assessment of EDCs. The end points
chosen are relevant for the ecologic risk assess-
ment process. Model compounds include tra-
ditional organochlorine pesticides and
industrial compounds, positive controls (estro-
gens and androgens), current use pesticides
(e.g., atrazine), and thyroid-active agents. The
chemicals chosen are timely and important rel-
ative to exposure, and low-dose effects and
latent effects are being addressed in a rigorous
manner. Thus, a good deal of high-quality data
are being developed under LTG 1, providing
the foundation for environmental risk assess-
ments and risk management of EDCs. 
The Research Plan has developed critical
and relevant information on mode of action,
interspecies differences, multiple chemical
exposures, critical life stages, dose–response
characteristics, effects at multiple levels of bio-
logical organization, linkages among assess-
ment end points, and low-dose effects of
EDCs. All of these findings are required for
the appropriate evaluation and risk assessments
of EDCs. 
Strengths and challenges. The scientific
expertise available in ORD and some of the
external STAR recipients are a primarystrength for LTG 1. The research program
structure and implementation is logical and
well designed, adding strengths in this key
area. Additionally, the models that are being
characterized to evaluate EDCs under LTG 3
will complement the on-going efforts in
LTG 1.
The EDC Program and scientists within
ORD provide strong leadership in the design
and execution of research efforts in this area.
The models that have been designed or modi-
fied to evaluate endocrine disruption will
provide the data required to develop risk
assessments. The models have been the subject
of harmonization efforts to be compatible
with Organisation for Economic Cooperation
and Development (OECD) guidelines for
toxicity testing.
The risk management program provides
important information for the regulated com-
munity with regard to identifying and priori-
tizing EDCs of concern and leadership in
developing risk management approaches.
The complexity of endocrine systems, in
conjunction with the diversity of potentially
endocrine-active chemicals makes the evalua-
tion of combined effects of EDCs a daunting
task. Even with a solid approach, good labora-
tory models, and adequate funding, it is likely
that it will be some years for ORD to fully
evaluate this question. 
Scientiﬁc expertise for the areas of human
and aquatic (ﬁsh, invertebrates, and amphib-
ians) species is very good. However, this same
strength is not apparent in the area of wildlife
toxicology, and much of the experimental
research and expertise comes in the way of
STAR grant recipients. It is certainly advanta-
geous to utilize the expertise of these scientists
from outside the agency; however, more exper-
tise in the area of wildlife toxicology within the
agency will be required to fully attain the goals
within this program and meet the exact needs
of regulatory concern. In addition the evalua-
tions of EDCs on wildlife within a risk assess-
ment paradigm, including evaluation of
uncertainties, would almost certainly require
full-time U.S. EPA personnel. Because of the
complexities in extrapolating among the many
species in the environment that may be
affected by endocrine disruptors, it will be
important for ORD to continue to collaborate
with other federal, academic, and nongovern-
mental organizations, and industry partners to
better characterize the range of variability
among species.
The model and framework for develop-
ment of critical information on EDCs for risk
assessment is well established and making
progress. Efforts should now focus on develop-
ment of risk assessment paradigms for EDCs
and application of the research findings. A
major challenge for risk assessment will be to
settle on definitions of what constitutes an
adverse effect and what constitutes a biological
indicator. This challenge does not reside exclu-
sively within ORD, but ORD research will be
needed to support decisions in this area.
The development of analytical methods
for detection and quantitation of EDCs is a
signiﬁcant challenge and was not clearly iden-
tiﬁed as an annual performance goal or annual
performance measure for this research. This
may slow the progress of the risk management
program. In addition, studies conducted by
investigators outside the U.S. EPA have
reported the use of predictive tools that can be
used to prioritize the focus of selective water
and wastewater treatment technologies. These
findings, as well as plans for future research
regarding natural processes in sediments,
could be integrated into this work. 
Long-term goal 2. LTG 2 seeks to deter-
mine the extent of the impact of endocrine
disruptors on humans, wildlife, and the envi-
ronment. The subcommittee evaluation of the
Research Plan and the MYP found that the
goals and science questions are appropriate and
represent an understandable and solid frame-
work for setting research priorities for
endocrine disruptors. The Research Plan has
stood the test of time and is appropriately
reﬂected in the MYP for LTG 2. 
The presentations and posters under
LTG 2 represented primarily issues of environ-
mental and human exposures to actual and sus-
pected EDCs, and the spectrum of effects that
might be produced from those exposures.
There is obvious overlap with the other long-
term goals. For example, one of the key science
questions of the MYP for LTG 2 is to deter-
mine how and to what degree human and
wildlife populations are exposed to EDCs
(Appendix 2). This question is also relevant to
LTG 1 goals such as those dealing with dose
response and exposure to mixtures of EDCs.
This overlap is desirable if it is understood that
the success of each of the long-term goals is
dependent on continued productive interac-
tions among all the projects covered under the
endocrine disruptor umbrella as well as related
activities in programs in human health, compu-
tational toxicology, risk assessment, risk man-
agement, and the needs of the regional ofﬁces.
To date, the U.S. EPA appears to have been
successful in linking different components of
the EDC Program.
In the case of environmental releases and
ecologic effects, the U.S. EPA has taken two
approaches: a) study chemicals with known
EDC activity and b) evaluate the endocrine
activity of emissions and releases from differ-
ent sources followed by attempts to identify
the chemicals responsible for the observed
activity. Both approaches are needed, but the
U.S. EPA should not lose sight of the goal of
determining chemical classes of interest and
the sources of EDCs. 
Strengths and challenges. The U.S. EPA
research program relevant to the science ques-
tions contained in LTG 2 has been productive,
of high quality, and relevant to the mission of
the U.S. EPA. Available resources have been
used efﬁciently, and both the intramural and
extramural investigators demonstrate a high
degree of enthusiasm for the projects. In
general, greater progress has been made on eco-
logic effects of EDCs compared with human
health effects, although several appropriate
human health projects are underway. 
Many of the models required for studying
ﬁsh and invertebrate effects of EDCs have been
developed, modiﬁed, and/or applied. Ongoing
studies have set appropriate priorities for deter-
mining sources of EDC exposures including
concentrated animal feedlot operations, com-
bustion processes, and pulp mills. The ecologic
studies have effectively coupled field studies,
biomarker measurements, analytical chemistry,
laboratory studies with whole organisms, and
hormone-responsive cells with effluents sus-
pected of possessing hormonal activity.
U.S. EPA scientists have made good deci-
sions on how to best use genomics, with a
good balance between molecular toxicology
and effects on aquatic species and experimental
animals. The information generated from these
studies should produce important data that
address critical knowledge gaps.
Interactions between ORD and the
regional offices on EDC issues are strong,
effective, and frequent and provide a good
model for the U.S. EPA to use in other areas.
The research within LTG 2 is consistent with
the overarching Research Plan developed by
the U.S. EPA and other agencies in 1998, with
research priorities reﬂecting the high-priority
goals identiﬁed by that plan.
Although priorities for chemicals studied
have been appropriate, the U.S. EPA should
strive to continue to improve its interactions
with other agencies with a strong interest in
the EDCs, such as the Centers for Disease
Control and Prevention (CDC), National
Institute of Environmental Health Sciences
(NIEHS), National Toxicology Program,
National Institute for Occupational Safety and
Health (NIOSH), and U.S. Food and Drug
Administration (FDA). These collaborations
will facilitate identifying new sources of envi-
ronmental and human exposures to EDCs.
Moreover, the U.S. EPA should mine data
made available from the High Production
Volume program (U.S. EPA 2005c) and work
with the U.S. FDA to investigate the role of
pharmaceuticals in the environment as a
source of endocrine disruptors.
The epidemiology studies represent an
important component of the EDC Program
relevant to LTG 2. The U.S. EPA is encour-
aged to continue these studies and to use
the exposure results to set priorities for future
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studies are kept to a minimum. The U.S.
EPA should continue to investigate the com-
mon ground between ecologic and human
health, as no other agency’s mission provides
this opportunity.
It will be important for the U.S. EPA to
take a leadership role in the application of
“omics” technologies to address many of the
science questions critical for evaluating envi-
ronmental and human health effects of EDCs.
Although there was evidence of considerable
progress in this regard, future development of
this approach will require a strong commit-
ment to a systems biology approach and com-
putational toxicology as well as effective
interactions with those generating much of the
basic data.
Long-Term Goal 3. The screening and
testing program of the U.S. EPA was estab-
lished to comply with the FQPA (1996) and
SDWA Amendments (1996). Principles for
screening and testing of chemicals for potential
endocrine-disrupting activity were developed
by the Endocrine Disruptor Screening and
Testing Advisory Committee (EDSTAC)
(U.S. EPA 1998b), a federal advisory commit-
tee convened by the U.S. EPA to provide rec-
ommendations on how to implement the
endocrine-disruptor assessment aspects of
FQPA and SDWA. EDSTAC recommended
that the evaluation of chemicals proceed in a
tiered manner: prioritization for assessment,
followed by screening for putative endocrine
activity, which would then be confirmed by
definitive testing. EDSTAC recommended
that the screening encompass effects on estro-
gen, androgen, and thyroid hormone function. 
The recommendations of EDSTAC have
served as the basis for the U.S. EPA EDSP (U.S.
EPA 2005b). ORD has taken the appropriate
steps through its MYP to develop tools for pri-
oritization, has standardized and validated assays
for screening, and has added sensitive end points
to traditional assessments of reproductive toxic-
ity that enable a more complete understanding
of the mechanisms of EDCs.
The research on screening and testing is
essential to the mission of the U.S. EPA and to
the mandates given to the U.S. EPA under the
FQPA (1996) and the SDWA Amendments
(1996). Virtually all of the short-term goals
(ﬁrst several years) identiﬁed under the MYP
are fully aligned with the recommendations of
EDSTAC and to the efforts of the U.S. EPA to
comply with the nature and timing of its
FQPA/SDWA mandates. Research support
and expertise from ORD have been at the fore-
front of developing, standardizing, and validat-
ing screens for endocrine disruptors. 
The program plan with respect to LTG 3
exceeds the explicit recommendations of
EDSTAC and takes advantage of improve-
ments in the science, especially in the realm of
computational biology. The U.S. EPA has
recently launched a national, multilaboratory
computational toxicology program that stands
to contribute significantly to endocrine dis-
ruptor screening, particularly through the
development of quantitative structure–activity
relationship (QSAR) models.
Strengths and challenges. The progress on
LTG 3 within the EDC Program has been
excellent. Two mammalian tests have already
been through a validation program adminis-
tered by the OECD. These should be available
for use by the EDSP very soon. Development
of the other two tests recommended by
EDSTAC is in progress, and publications ema-
nating from this work indicate that the work is
on track. 
There has been signiﬁcant progress within
ORD and its scientiﬁc partners in the develop-
ment and validation of several relevant bioas-
says important for the screening and testing
requirements for LTG 3. The uterotrophic
assay for estrogenic effects and the Hershberger
assay for androgenic effects have been the sub-
ject of multilaboratory, multinational valida-
tion programs coordinated by OECD, with
considerable guidance from ORD scientists.
The pubertal male and female assays, which
evaluate the attainment of puberty in rodents
and are semiapical in that they assess the inte-
grated function of a number of mechanisms of
action (hormone synthesis, hormone action,
endocrine axes), are still under development
via ORD research programs. ORD included
the completion of these as short-term goals in
its MYP. 
In vitro assays for androgen receptor (AR)
and estrogen receptor (ER) binding have been
developed and validated. Moreover, in vitro
AR- and ER-dependent transactivation assays
in transformed cell lines are now available, and
these use both stable and transiently trans-
fected cells. These assays, coupled with on-
going studies in other laboratories, suggest that
this important screening component of LTG 3
is nearly complete. In addition, an in vitro
assay for determining the effects of EDCs on
steroidogenesis has been developed, and the
approach will be capable of measuring both
modulation of steroidogenic gene expression
and activity. This bioassay seems highly
promising and requires further validation using
more extensive sets of test EDCs and possibly
development of alternate cell lines to determine
possible intercellular differences in response to
EDCs. Excellent progress has also been made
on validation of short-term in vivo assays for
the determination of estrogenic/antiestrogenic
and androgenic/antiandrogenic chemicals,
using the rat as a model. 
The EDC research is mechanistically dri-
ven, which provides a solid scientiﬁc founda-
tion for the test methods that are developed.
Because of this mechanistic focus, it is highly
likely that the methods developed will be valid,
broadly applicable, and easily interpreted.
Clear goals are articulated for the develop-
ment of screening and testing methods for
endocrine disruption. U.S. EPA research is well
coordinated with other federal agencies and
with international efforts on the standardiza-
tion and validation of endocrine-screening
assays. ORD has been highly responsive to the
needs of the EDSP (U.S. EPA 2005b) and has
provided technical expertise to the Office of
Science Coordination and Policy. ORD has
used its leadership role in the ﬁelds of repro-
ductive, developmental, endocrine, and aquatic
toxicology to adapt and develop methods that
have high relevance to the needs of the pro-
gram offices and to the protection of public
and environmental health. 
The major challenge that ORD has faced is
handing off its research to the program ofﬁces
so that validation and implementation can
occur in a timely manner. Much of the delay in
validation and regulatory acceptance, however,
is because this process takes place largely outside
the agency. The transfer of protocols to con-
tract laboratories has been problematic. This
has led to a) a substantial commitment by the
U.S. EPA staff to reﬁne and troubleshot assays,
and b) a negative effect on other core research
activities that are the responsibility of the U.S.
EPA staff. The subcommittee recommends that
there be a mechanism in place to ensure the
timely transition of protocols to the OPPTS.
Research within NHEERL has contributed
to basic understanding of the toxic responses 
to estrogens, antiandrogens (within the
Reproductive Toxicology Division) and thy-
roid toxicants (within the Experimental
Toxicology Division), which in turn has led
directly to the development of improved meth-
ods for EDC detection. This research is diffuse
and is occurring in multiple divisions within
NHEERL; many of the accomplishments in
these areas have been difﬁcult to capture in the
list of annual performance goals. The subcom-
mittee recommended that the U.S. EPA try to
summarize this research and its relevance to
EDC identiﬁcation in subsequent reports and
revisions of the MYP.
ORD is beginning to develop core compe-
tencies in genomics and QSAR methods, both
of which hold promise in EDC identiﬁcation.
Because these areas are so data intensive, it will
be important for ORD to train or hire experts
in bioinformatics to work with the life sciences
experts already on staff.
Program Leadership and
Resources
The EDC Program has enjoyed outstanding
leadership since its inception in 1995. The
EDC Program scientists consult with and pro-
vide technical assistance to other U.S. EPA
program offices, other federal agencies, and
U.S. EPA Endocrine Disrupting Chemicals Program review
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scientists are engaged in intramural and extra-
mural research within ORD, and program sci-
entists have provided exemplary leadership in
the ﬁeld at the national and international level.
The EDC scientists are at the forefront of
research in this field in EDC screening and
testing methodologies for mammalian and eco-
logic tests, source identification, effects on
wildlife, and ecologic health. 
The EDC Program is unique in that no
other U.S. federal agency has an EDC pro-
gram with such broad responsibilities. The
EDC Program is not just an umbrella for a
series of independent project but a fully inte-
grated program across all the laboratories and
centers (with the exception of the Homeland
Security Research Center). The program is
nationally and internationally recognized as a
multidisciplinary set of research projects for
both human health and wildlife and cuts
across the risk assessment/risk management
paradigm. 
The EDC Program was projected to have
an average annual budget of $12 million. This
figure includes the STAR grants program,
which averages $4 million in years when it is
funded. In actuality, the average annual bud-
get from fiscal year (FY) 2003–2005 has
ranged from $12.7 million enacted in 2003 to
the FY 2005 request of $8.0 million, which
includes approximately 55 full-time equivalent
personnel per year. The EDC Program direc-
tor does not have direct access to human or
ﬁnancial resources to carry out the objectives of
the program. Instead, the director must negoti-
ate with the division heads of the laboratories
and centers of ORD to use the time and effort
of scientists with the needed expertise. 
The laboratories and center that contribute
resources to the EDC Program are NRMRL,
National Center for Environmental Research
(NCER), NERL, and NHEERL. Although
the total budget for the program has decreased
since FY 2003 (from $12.7 million to an $8.0
million request for FY 2005), the percentage of
resources provided by each of these laboratories
has been relatively stable (except for NCER)
over the past 2 years and is in proportion to the
number and extent of tasks that they perform
for the EDC Program across the long-term
goals. The STAR grants program adds signiﬁ-
cant value to the research portfolio of the EDC
Program. The research sponsored by the STAR
program assists in filling identified research
gaps, brings in research expertise that is not
found among intramural scientists, and assists
the ORD in responding to new issues that the
laboratories and centers may not be able to
readily address. 
The manner in which this program is
funded, though indirect and possibly cumber-
some, does not appear to hinder the quality of
the research being done in the program. It is
apparent that the EDC Program director has
had success in convincing division directors to
loan scientist time to the EDC Program. It
does make it more difﬁcult, however, for the
program director to do forward planning or to
plan to investigate emerging issues. ORD has
been very astute in leveraging the resources of
the EDC Program by collaborating with other
federal agencies. The amount of research done
by the EDC Program has been expanded by
collaboration with agencies such as NIOSH,
NIEHS, and the National Cancer Institute;
however, the fragmentation of scientists’ time
without compensation raises concern about
whether the productivity (number of manu-
scripts published, etc.) of these scientists is
negatively impacted by participation in the
EDC Program. 
The situations cited above (insufficient
funding and the mechanism used to provide
resources to the EDC Program) can be reme-
died by several courses of action: a) hiring
additional personnel to share the workload of
the participating laboratories; b) elevating the
position of the EDC Program director to the
level of the laboratory/center directors; and
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Charge Question 1. Program design
• Do the goals and priorities of the Endocrine Disruptors Research Plan
(Research Plan) and MYP, including the MYP’s long-term goals (LTGs)
of the MYP, represent appropriate outcome measures for this program?
• Has the research program appropriately implemented the Research
Plan and the Office of Research and Development (ORD) MYP,
tracking the key science questions closely and describing clearly the
expectations for providing answers to the key science questions?
• Do the Research Plan and MYP of the ORD make it clear what the
unique research niche of the ORD is in the context of endocrine
disruptors research being conducted across the federal government
and internationally? Is the rationale sound for supporting the
choices that ORD has made in the past and for the future regarding
what to emphasize over the next 5–7 years? If not, what arguments
need to be more clearly stated, and what additional evidence and
information need to be included? 
• Have the potential public beneﬁts of the Research Plan been clearly
articulated? Are there interagency collaborations that should and
can be improved to advance the research agenda of the agency? Too
what extent has the U.S. EPA established and utilized other agen-
cies (inside and outside the government) in advancing the research
agenda of the U.S. EPA? What are the impediments to collabora-
tion with other organizations?
• Are the research products (annual performance measures) and their
sequencing and emphases over the next approximately 5–7 years
appropriate, especially in light of needs for the Endocrine Disruptor
Screening Program by the Office of Prevention, Pesticides and
Toxic Substances? Does the program have a complete schedule with
annual milestones for decisions and termination points, highlight-
ing changes from previous schedules?
• Is the MYP sufﬁciently ﬂexible to adapt to anticipated future science
and policy direction changes? 
Charge Question 2. Program relevance
• To what extent has the research program, as evidenced by the
Research Plan, the ORD MYP, National Health Effects and and
Research Laboratory Implementation Plan, and other submitted
documentation been responsive to agency and other stakeholder
needs and priorities?
• What role have program scientists had in providing technical sup-
port to agency program and regional ofﬁces?
Charge Question 3. Program progress in addressing key scientiﬁc
questions and impacting environmental decision making
• What degree of progress has been made in addressing each of the
LTGs and associated key research questions?
• To what degree are scientiﬁc products being used in environmental
decision making?
• Has the Research Plan met its annual performance goals?
Charge Question 4. Program contributions to scientiﬁc leadership
• To what extent have the program and its scientists contributed to
advancing the state of science on endocrine disruptors?
Charge Question 5. Program resource allocation
• The MYP was developed based on an assumption of level resources
(approximately $12 million including approximately 55 full-time
equivalent personnel) over the period covered by the plan.
• Is the relative allocation of resources across the LTGs adequate
based on consideration of scientiﬁc and programmatic needs?
• Is the manner in which resources are allocated appropriate?
• Do these funding processes maintain program quality?
Appendix 1. Charge questions for Endocrine Disrupting Chemicals Research Program review.c) giving the EDC Program director budget
authority. These actions would allow the pro-
gram director to negotiate for needed research
expertise from a position of strength and allow
the program director to enhance the laborato-
ries that participate in EDC Program research.
The ORD has plans to enact the latter two of
these ideas in the near future for all newly
hired national program directors. 
Conclusions 
The goals and science questions are appropriate
and represent an understandable and solid
framework for setting research priorities for
EDCs. The Research Plan was formalized in
1998 after a series of workshops, interagency
considerations, and meetings that embraced all
relevant stakeholders. The program is nation-
ally and internationally recognized as a multi-
disciplinary set of research areas for both
human health and wildlife and cuts across the
risk assessment/risk management paradigm.
Key research areas are closely aligned to the
LTGs and annual performance goals. The
EDC Program is a combination of problem-
driven and core research that has stood the test
of time. 
The subcommittee is favorably impressed
with the quality and relevance of the work and
the progress to date, although we recognize
that much remains to be done. The annual
performance goals are highly ambitious and it
should be recognized that progress on those
goals will, in most cases, continue well past the
initial timelines. We are impressed with the
enthusiasm of the investigators and their com-
mitment to addressing the difﬁcult and contro-
versial issues that surround endocrine-disruptor
research. 
One of the main functions of the U.S. EPA
is risk assessment and risk management of
chemicals in commerce and the environment.
LTG 1 provides a solid scientiﬁc foundation for
conducting risk assessments and making risk
management decisions related to endocrine
disruptors. The research that falls under this
goal covers the major questions in the key areas
of the risk paradigm. Although there are many
challenges to fully deﬁning the nature of possi-
ble biological effects and the extent of expo-
sure, the research being carried out under this
long-term goal will put the U.S. EPA in a
strong position to make scientiﬁcally grounded
decisions.
The research program relevant to the sci-
ence questions contained in LTG 2 has been
productive, of high quality, and relevant to the
mission of the U.S. EPA. Available resources
have been used efﬁciently, resulting in a high
degree of enthusiasm for the projects by both
the intramural and extramural investigators. In
general, greater progress has been made on eco-
logic effects of EDCs compared with human
health effects, although several appropriate
human health projects are underway. 
The progress on LTG 3 within the EDC
Program has been excellent. Two mammalian
tests have already been through a validation
program administered by OECD. These
should be available for use by the EDSP very
soon. Development of the other two tests rec-
ommended by EDSTAC is in progress, and
publications emanating from this work indi-
cate that the work is progressing appropriately
on track. ORD has articulated clear goals for
the development of screening and testing
methods for endocrine disruption and is fulﬁll-
ing those goals in an admirable fashion. The
research is directly relevant to legislation that
the U.S. EPA administers and is serving the
program ofﬁces well. Research of the U.S. EPA
is well coordinated with other federal agencies
and with international efforts on the standard-
ization and validation of endocrine-screening
assays. 
Despite good progress, the future success of
the U.S. EPA in meeting the speciﬁed goals of
the EDC Program will depend on a number of
factors, including a) strengthening their exper-
tise in wildlife toxicology; b) expediting valida-
tion of the EDSTAC tests; and c) taking a
leadership role in the application of omics
technologies to address many of the science
questions critical for evaluating environmental
and human health effects of EDCs. In addi-
tion, support from U.S. EPA management,
multidisciplinary intramural research spanning
ORD and other U.S. EPA entities, extramural
grants, and continued interagency collabora-
tions (e.g., NIEHS, CDC, U.S. Geological
Survey, U.S. FDA, U.S. Department of
Agriculture, and others), especially with regard
to identifying new sources of environmental
and human exposure, will be critical. To date,
the EDC Program has been very astute in
leveraging its resources by collaborating with
other federal agencies and has extended its
research program as a result of these collabora-
tions. The continuation of the external grants
program, in particular the STAR grants pro-
gram, is vital, as it provides a mechanism for
the U.S. EPA to more efﬁciently evaluate new
technologies and innovations for use in the risk
assessment and risk management arenas. 
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Appendix 2. Key research
questions and relationship 
to long-term goals in the 
U.S. EPA EDC Multi-Year Plan.
Long-Term Goal 1. Provide a better under-
standing of science underlying the effects,
exposure, assessment, and management of
endocrine disruptors.
• What approaches are needed to assess risks
to humans and wildlife? 
• What are the dose–response characteristics
in the low-dose region? 
• What extrapolation tools are needed? 
• What are the effects of exposure to multiple
EDCs, and will a toxic equivalency factor
approach be feasible? 
• What is the nature and manifestation of
latent effects from developmental exposures
to EDCs? 
• How can unreasonable risks be managed? 
Long-Term Goal 2. Determine the extent
of the impact of endocrine disruptors on
humans, wildlife, and the environment.
• What effects are occurring in exposed
humans and wildlife populations? 
• What are the chemical classes of interest
and their potencies? 
• How and to what degree are human and
wildlife populations exposed to EDCs? 
• What are the major sources and environ-
mental fates of EDCs? 
Long-term Goal 3. Support the screening
and testing program of the U.S. EPA.
• Do our testing guidelines adequately evalu-
ate potential endocrine-mediated effects?Harding et al.
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